重症监护临床试验中的持续同意:范围综述及报告建议
该范围综述筛查了5454项重症监护随机对照试验,其中159项(2.9%)使用了持续同意,多数(80.5%)与前瞻性同意联合使用。99.4%的研究来自高收入地区,81.1%发表于近10年。仅39项试验按同意方法分别报告了同意率。23项探讨持续同意体验的研究显示,适当时机、清晰沟通和感知临床获益可增强可接受性,而对自主性、感知风险和死后同意的担忧降低支持度。作者认为共同设计的教育与实施资源及更好的报告标准可能提升采纳度和透明度。
要点
- 在5454项重症监护随机对照试验中,仅159项(2.9%)使用持续同意,其中成人试验133/3743(3.6%)、儿科13/567(2.3%)、新生儿13/1144(1.1%)。
- 持续同意单独使用仅26/159(16.4%),多数(128/159,80.5%)与另一种同意方式(主要为前瞻性同意)联合使用。
- 仅39项随机对照试验按同意方法分别报告了同意率,报告标准有待统一。
- 23项探讨体验的研究提示,适当时机、清晰沟通和感知临床获益可增强持续同意的可接受性。
- 对自主性、感知风险和死后同意的担忧会降低对持续同意的支持度。
适用人群与场景
- 重症监护随机对照试验的受试者,包括成人、儿科和新生儿人群。
- 急性临床场景中需在获得同意前启动干预并入组试验的患者。
研究设计与关键结果
- 研究类型为范围综述,筛查5454项重症监护随机对照试验,其中159项使用持续同意(2.9%);成人133/3743(3.6%)、儿科13/567(2.3%)、新生儿13/1144(1.1%)。
- 持续同意单独使用26/159(16.4%),与另一种同意方式联合使用128/159(80.5%),主要为前瞻性同意。
- 158/159(99.4%)的研究来自高收入地区,81.1%发表于过去10年;仅39项随机对照试验按同意方法分别报告同意率。
- 23项探讨持续同意体验的研究显示,适当时机、清晰沟通和感知临床获益增强可接受性,而对自主性、感知风险和死后同意的担忧降低支持度。
证据类型、等级与局限
- 证据类型:范围综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,共同设计的教育与实施资源以及更好的报告标准,可能提升持续同意的采纳度和透明度,最终提高研究质量与临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: In acute clinical scenarios, consent-to-continue (CTC) permits patient enrolment into clinical trials, and commencement of intervention, prior to obtaining consent. Consent, for continuation in the trial, is then sought once the emergent situation has passed. Despite implementation of CTC in intensive care unit (ICU) research, there are few studies investigating implementation and acceptability of this approach. Our objective was to describe implementation, experiences, and determinants of acceptability of CTC for ICU randomised controlled trials (RCTs).
METHODS: A scoping review was conducted. Academic databases, and databases of ICU RCTs, were used to identify studies that reported the results of RCTs and/or the views and acceptability of CTC.
RESULTS: 5,454 ICU RCTs were screened. 159 RCTs used CTC (2.9% of all ICU RCTs; 13/1,144 [1.1%] neonatal RCTs, 13/567 [2.3%] paediatric RCTs, 133/3,743 [3.6%] adult RCTs). CTC was used either alone (26/159; 16.4%) or in combination with another consent approach, predominantly prospective consent (128/159; 80.5%). 158/159 (99.4%) of studies were led from high-income settings and most (81.1%) were published in the past 10 years. Only 39 RCTs reported consent rates separately by method of consent. Analysis of 23 studies exploring experience of CTC revealed factors that enhanced acceptability included appropriate timing, clear communication, and perceived clinical benefit, whereas concerns about autonomy, perceived risk, and post-mortem consent reduced support.
CONCLUSIONS: Despite many jurisdictions allowing CTC, it is still uncommon in ICU RCTs. These results will inform the development of future processes and materials to enhance understanding, implementation and reporting of CTC.
IMPLICATIONS FOR CLINICAL PRACTICE: Co-designed educational and implementation resources, alongside better reporting standards, may enhance adoption and transparency, ultimately strengthening research quality and clinical outcomes.
参考来源
- Gibbons KS, Le Marsney R, Cucchi M, et al. Consent-to-continue in intensive care clinical trials: A scoping review and recommendation for reporting. Intensive Crit Care Nurs. 2026. PMID: 41936252. doi:10.1016/j.iccn.2026.104410
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。